6.4557
2.87%
0.1757
전일 마감가:
$6.28
열려 있는:
$6.28
하루 거래량:
284.69K
Relative Volume:
0.36
시가총액:
$229.75M
수익:
-
순이익/손실:
$-144.01M
주가수익비율:
-1.9445
EPS:
-3.32
순현금흐름:
$-113.02M
1주 성능:
-9.14%
1개월 성능:
-42.53%
6개월 성능:
-44.21%
1년 성능:
-35.01%
바이오미아 퓨전 Stock (BMEA) Company Profile
명칭
Biomea Fusion Inc
전화
(650) 980-9099
주소
900 MIDDLEFIELD ROAD, REDWOOD CITY
BMEA을(를) 다른 주식과 비교
주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
---|---|---|---|---|---|---|
BMEA | 6.44 | 229.75M | 0 | -144.01M | -113.02M | -3.32 |
VRTX | 450.61 | 115.43B | 10.63B | -479.80M | -1.35B | 13.33 |
REGN | 749.05 | 82.04B | 13.85B | 4.65B | 3.32B | 35.06 |
ARGX | 589.59 | 35.30B | 1.86B | -40.29M | -1.28B | -4.16 |
ALNY | 247.41 | 32.04B | 2.09B | -332.26M | 16.06M | -4.14 |
BNTX | 106.82 | 24.89B | 3.30B | -501.07M | 1.03B | 11.54 |
바이오미아 퓨전 Stock (BMEA) Upgrades & Downgrades
날짜 | 액션 | 분석자 | 등급 변경 |
---|---|---|---|
2024-10-09 | 개시 | Edward Jones | Buy |
2024-09-27 | 업그레이드 | Rodman & Renshaw | Neutral → Buy |
2024-09-27 | 업그레이드 | Truist | Hold → Buy |
2024-08-29 | 개시 | CapitalOne | Overweight |
2024-06-11 | 다운그레이드 | Truist | Buy → Hold |
2024-06-07 | 다운그레이드 | Barclays | Overweight → Equal Weight |
2024-04-02 | 다운그레이드 | JP Morgan | Overweight → Neutral |
2024-02-06 | 개시 | Truist | Buy |
2023-07-27 | 개시 | Scotiabank | Sector Outperform |
2023-06-26 | 다운그레이드 | Jefferies | Buy → Hold |
2023-05-12 | 개시 | Barclays | Overweight |
2023-03-29 | 재확인 | Oppenheimer | Outperform |
2023-03-28 | 재확인 | H.C. Wainwright | Buy |
2023-02-24 | 개시 | Citigroup | Buy |
2022-06-02 | 재개 | H.C. Wainwright | Buy |
2022-01-12 | 개시 | H.C. Wainwright | Buy |
2021-12-17 | 개시 | Oppenheimer | Outperform |
2021-05-11 | 개시 | JP Morgan | Overweight |
2021-05-11 | 개시 | Jefferies | Buy |
2021-05-11 | 개시 | Piper Sandler | Overweight |
모두보기
바이오미아 퓨전 주식(BMEA)의 최신 뉴스
HC Wainwright Reiterates Buy Rating for Biomea Fusion (NASDAQ:BMEA) - MarketBeat
Late-Breaker Oral Presentation Showing New Analysis from - GlobeNewswire
Biomea Fusion's Diabetes Drug Shows 1.23% HbA1c Drop in Key Patient Group | BMEA Stock News - StockTitan
(BMEA) Investment Report - Stock Traders Daily
We're A Little Worried About Biomea Fusion's (NASDAQ:BMEA) Cash Burn Rate - Yahoo Finance
How To Trade (BMEA) - Stock Traders Daily
Biomea Fusion, Inc. Reveals Preclinical Data on Icovamenib and BMF-650 in Recent SEC Filing - Defense World
Biomea Fusion's SWOT analysis: clinical hold clouds diabetes drug stock outlook - Investing.com India
Biomea Fusion FY2024 EPS Estimate Raised by HC Wainwright - Defense World
HC Wainwright Forecasts Increased Earnings for Biomea Fusion - MarketBeat
Biomea Fusion (NASDAQ:BMEA) Stock Price Expected to Rise, Piper Sandler Analyst Says - Defense World
Biomea Fusion’s (BMEA) “Buy” Rating Reaffirmed at HC Wainwright - Defense World
BMEABiomea Fusion, Inc. Latest Stock News & Market Updates - StockTitan
Biomea Fusion, Inc. Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4) - StockTitan
Biomea Fusion stock PT raised by Piper Sandler, citing pipeline potential - Investing.com Australia
HC Wainwright Reiterates "Buy" Rating for Biomea Fusion (NASDAQ:BMEA) - MarketBeat
Biomea Fusion Unveils Promising Diabetes Treatment Innovations - TipRanks
Biomea Fusion Reports Q3 2024 Financial Results - MSN
Biomea Fusion Presents Preclinical Data Showing Icovamenib (BMF-219) Enhanced Effectiveness of GLP-1-Based Therapies and Introduces BMF-650, a Next-Generation, Oral Small-Molecule GLP-1 Receptor Agonist Candidate - GlobeNewswire
Barclays Forecasts Strong Price Appreciation for Biomea Fusion (NASDAQ:BMEA) Stock - MarketBeat
Biomea Awaits 2 Data Readouts Of Diabetes StudiesCan The Stock Get Its Mojo Back? - RTTNews
Biomea Fusion (NASDAQ:BMEA) Announces Earnings Results - MarketBeat
Biomea Fusion price target raised to $11 from $9 at Barclays - TipRanks
Biomea Fusion reports Q3 EPS (91c), consensus (95c) - TipRanks
Biomea Fusion Reports Third Quarter 2024 Financial Results and Corporate Highlights - The Manila Times
Biomea Fusion options imply 6.1% move in share price post-earnings - TipRanks
Biomea Fusion, Inc. (NASDAQ:BMEA) Given Average Rating of "Buy" by Brokerages - MarketBeat
Biomea Fusion, Inc. (NASDAQ:BMEA) Receives Consensus Rating of “Buy” from Brokerages - Defense World
(BMEA) Technical Data - Stock Traders Daily
Biomea Fusion shares maintain Buy rating from H.C. Wainwright By Investing.com - Investing.com Australia
Biomea Fusion's (BMEA) Buy Rating Reiterated at HC Wainwright - MarketBeat
Biomea Fusion shares maintain Buy rating from H.C. Wainwright - Investing.com
Exchange Traded Concepts LLC Acquires 8,079 Shares of Biomea Fusion, Inc. (NASDAQ:BMEA) - Defense World
Biomea Fusion's icovamenib gets global and US naming approval - Investing.com India
Biomea Fusion's icovamenib gets global and US naming approval By Investing.com - Investing.com South Africa
Biomea Fusion announces approval of ‘icovamenib’ as INN for BMF-219 - TipRanks
Biomea Fusion Announces Approval of 'icovamenib” as International Nonproprietary Name for BMF-219 - The Manila Times
Biomea Fusion Announces Approval of “icovamenib” as International Nonproprietary Name for BMF-219 - GlobeNewswire
Biomea Fusion (NASDAQ:BMEA) & Acrivon Therapeutics (NASDAQ:ACRV) Financial Survey - Defense World
(BMEA) Investment Analysis and Advice - Stock Traders Daily
Griffin Asset Management Inc. Purchases 57,180 Shares of Biomea Fusion, Inc. (NASDAQ:BMEA) - MarketBeat
Biomea Fusion to Host Conference Call and Webcast on Wednesday, October 30th at 4:30 pm ET to Announce Our Lead Clinical Candidate, BMF-650, a Next-Generation, Oral Small-Molecule GLP-1 Receptor Agonist and Preclinical Data Combining BMF-21 - The Manila Times
Marshall Wace LLP Sells 3,900 Shares of Biomea Fusion, Inc. (NASDAQ:BMEA) - Defense World
Squarepoint Ops LLC Takes Position in Biomea Fusion, Inc. (NASDAQ:BMEA) - MarketBeat
Investigation Launched into Biomea Fusion Securities - Bit Perfect Solutions
바이오미아 퓨전 (BMEA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
자본화:
|
볼륨(24시간):